CRESSKILL, N.J. and JERUSALEM, Israel, June 07, 2021 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Firm”), a worldwide chief in superior noninvasive neurostimulation remedies of psychological well being problems, immediately introduced the Firm will take part within the upcoming international medical conferences:
- Clinical TMS Society Annual Meeting from June 10-12. The Annual Assembly of the Scientific TMS Society gives a singular alternative to attach with TMS suppliers and researchers from all over the world. Seven poster displays will spotlight the advantages and potential of Deep TMS™ remedy for psychological well being problems. Moreover, the Firm shall be internet hosting two showcase displays that includes novel analysis and the medical utility of Deep TMS.
- Psych Congress Elevate: Virtual Experience from June 11- 13. The worldwide convention brings collectively early profession and future-focused clinicians presenting a singular alternative to attach on the newest improvements, therapies, and analysis. Deep TMS supplier David Feifel MD, PhD, Director at Kadima Neuropsychiatry Institute, shall be collaborating within the showcase presentation, “Past Despair: Proof for Deep TMS in OCD and Smoking Cessation” on Friday, June 11, 2021 from 5:00-5:30 p.m. EST.
“We’re excited to attach and take part in these two society conferences, each centered on advancing the sector of psychological well being with leading edge remedies and techniques,” stated Christopher Boyer, Vice President of International Advertising at BrainsWay. “These attending have a direct and optimistic impression on affected person lives and are aligned with our dedication to advancing noninvasive remedy choices for psychological well being problems.”
BrainsWay is a worldwide chief in superior noninvasive neurostimulation remedies for psychological well being problems. The Firm is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform know-how to enhance well being and remodel lives. BrainsWay is the primary and solely TMS firm to acquire three FDA-cleared indications backed by pivotal research demonstrating clinically confirmed efficacy. Present indications embrace main depressive dysfunction, obsessive-compulsive dysfunction, and smoking dependancy. The Firm is devoted to main by superior science and constructing on its unparalleled physique of medical proof. Extra medical trials of Deep TMS in numerous psychiatric, neurological, and dependancy problems are underway. Based in 2003, with places of work in Cresskill, NJ and Jerusalem, Israel, BrainsWay is dedicated to growing international consciousness and broad entry to Deep TMS. For the newest information and details about BrainsWay, please go to www.brainsway.com.
Ahead Trying Statements
This press launch accommodates “forward-looking statements” throughout the that means of the Non-public Securities Litigation Reform Act of 1995. Such statements could also be preceded by the phrases “intends,” “could,” “will,” “plans,” “expects,” “anticipates,” “initiatives,” “predicts,” “estimates,” “goals,” “believes,” “hopes,” “potential” or related phrases. These forward-looking statements and their implications are based mostly on the present expectations of the administration of the Firm solely and are topic to numerous components and uncertainties that might trigger precise outcomes to vary materially from these described within the forward-looking statements. The next components, amongst others, may trigger precise outcomes to vary materially from these described within the forward-looking statements: inadequacy of monetary sources to satisfy future capital necessities; adjustments in know-how and market necessities; delays or obstacles in launching and/or efficiently finishing deliberate research and medical trials; failure to acquire approvals by regulatory companies on the Firm’s anticipated timeframe, or in any respect; incapability to retain or entice key staff whose data is crucial to the event of Deep TMS merchandise; unexpected difficulties with Deep TMS merchandise and processes, and/or incapability to develop needed enhancements; surprising prices associated to Deep TMS merchandise; failure to acquire and keep ample safety of the Firm’s mental property, together with mental property licensed to the Firm; the potential for product legal responsibility; adjustments in laws and relevant guidelines and rules; unfavorable market notion and acceptance of Deep TMS know-how; insufficient or delays in reimbursement from third-party payers, together with insurance coverage corporations and Medicare; incapability to commercialize Deep TMS, together with internationally, by the Firm or by third-party distributors; product growth by opponents; incapability to well timed develop and introduce new applied sciences, merchandise and purposes, and the impact of the worldwide COVID-19 well being pandemic on our enterprise and continued uncertainty and market impression relating thereto.
Any forward-looking assertion on this press launch speaks solely as of the date of this press launch. The Firm undertakes no obligation to publicly replace or evaluate any forward-looking assertion, whether or not because of new data, future developments or in any other case, besides as could also be required by any relevant securities legal guidelines. Extra detailed details about the dangers and uncertainties affecting the Firm is contained below the heading “Danger Components” within the Firm’s filings with the U.S. Securities and Trade Fee, together with the Firm’s Annual Report on Kind 20-F. Buyers and safety holders are urged to learn these paperwork freed from cost on the SEC’s website at http://www.sec.gov.
SVP and Chief Monetary Officer